The Canadian companies are combining a new drug delivery mechanism and bioproduction platform to enable what they believe will be a more cost-effective, scalable, and sustainable way to mass-produce therapeutic recombinant proteins.

Future Fields' platform, called the EntoEngine, would be used to mass-produce the novel protein now in development. Production would be more cost-effective than conventional approaches to biopharmaceutical production, the firms said.

Using CRISPR, Montreal-based Jenthera Therapeutics has developed an in vivo delivery mechanism for protein-based drugs via intravenous injection, eliminating the use of viruses, lipids, or nanoparticles, which are expensive to produce and require large manufacturing facilities.

Leveraging production with the EntoEngine, Jenthera can deliver tailored gene-editing complexes that selectively target the genomes of cancer cells, delivering in vivo anticancer therapeutics, the firms said.

The direct delivery of the ribonucleoprotein presents the optimal safety profile, they said, adding that in clinically relevant models in vivo, Jenthera's gene-editing complexes have shown high efficacy and tolerance, excellent bio distribution, and safety from off-targets and immunogenicity.

Edmonton, Alberta-based Future Fields is advancing a new biomanufacturing paradigm by harnessing fruit flies. With its biomanufacturing platform, the EntoEngine, the company is focused on making significant strides to increase the supply of recombinant proteins for biological drugs, shrink the cost of research and development, and diminish the carbon footprint of bioreactors. Future Fields said it is engaging with biotech companies to form research collaborations for strategic proteins of interest.

Bioengineered drug fights Staphylococcus infection
Early tests show that a bioengineered drug can counter infection with Staphylococcus aureus, a major cause of death in hospital patients. The...

Survey finds physicians are comfortable prescribing Humira biosimilars if treatments are interchangeable
Most specialist physicians would be comfortable prescribing biosimilar versions of adalimumab (Humira), giving a boost to the companies seeking to capitalize...

Protillion Biosciences raises $18M in financing to support therapeutic biomarker discovery
Protillion Biosciences, a privately held biotech company launched in 2019 to identify and optimize new protein therapeutics, on Monday announced the completion...

Rice University lab receives $3M grant to develop HIV treatment
Researchers from Rice University have been awarded a $3 million grant from the Bill & Melinda Gates Foundation to develop a once-a-year treatment for...

Bio-Rad launches new antibody discovery platform
Bio-Rad Laboratories has launched the Pioneer Antibody Discover Platform, a new antibody discovery service designed to develop "best-in-class" biologic...